omalizumab for asthma a new old hope?
About 5 million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to properly control their condition, resulting in frequent, severe and life-threatening seizures. A new study on the drug Omalizumab (Eng. ” Omalizumab “) gives hope to these patients.
This drug is an approved therapy for people not responding to steroid treatment. Scientists are trying to determine which biomarkers change during treatment. This will enable rapid identification of those patients who benefit the most from Omalizumab treatment .
Comment: Omalizumab is a drug that binds IgE antibodies . It is assumed that a decrease in the amount of antibodies in the body of an asthmatic will reduce the chain of antibody -binding reactions and the release of histamine with the subsequent development of allergic reactions. But the fact is that the excess part of histamine produced in the intestine does not depend on histamine release from mast cells. Therefore, a revolution in the treatment of asthma with the advent of these drugs did not happen. Moreover, omalizumab for asthma and its analogues have been “lit up” among the “panacea” lists for several years now. But the results of its application are very modest, if not doubtful.